PFS
Figure 5. · Panel A
Panel A 是同一 Figure 5. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Vincent Camus, Thierry Molina, Fabienne Desmots, Paul Blanc-Durand, Salim Kanoun, Amine Moslemi, Philippe Ruminy, Steven Le Gouill, Hervé Ghesquières, Lucie Oberic, Franck Morschhauser, Hervé Tilly, Vincent Ribrag, Roch Houot, Catherine Thieblemont, Hervé Maisonneuve, Fabien Claves, Krimo Bouabdallah, Corinne Haioun, Gandhi Laurent Damaj, Luc-Matthieu Fornecker, Robin Noel, Pierre Feugier, David Sibon, Guillaume Cartron, Christophe Bonnet, Wivine Bernard, Françoise Kraeber-Bodéré, Caroline Bodet-Milin, Jean-Philippe Jais, Josette Brière, Cedric Rossi, Mad-Hélénie Elsensohn, Loïc Chartier, Emmanuel Itti, Fabrice Jardin, Thierry Fest
Blood Adv 9(9) 2232-2246
The GAINED study was a randomized phase 3 trial comparing obinutuzumab (G) with rituximab (R) plus ACVBP (doxorubicin, cyclophosphamide, and prednisone, combined with either vindesine or bleomycin) or CHOP14 (cyclophosphamide, doxorubicin, vincristine, and prednisone, administered on a 14-day schedule) induction, followed by positron emission tomography (PET)-guided consolidation. This post hoc analysis aimed to detail the outcomes of patients with primary mediastinal B-cell lymphoma (PMBL), verified through expert pathological review and the use of gene expression profiling (GEP) and next-generation sequencing. Of 620 centrally reviewed patients, 138 (22.3%) confirmed PMBL cases were analyzed. Baseline characteristics included a median age of 33.5 years, 63.8% female, 55.1% stage III to IV, 90.6% elevated lactate dehydrogenase, 87.6% Eastern Cooperative Oncology Group performance status score of 0 to 1, 62.3% extranodal involvement, 52.6% age-adjusted International Prognostic Index (aaIPI) of 2% to 3%, and 53.6% bulk (>10 cm). Induction regimens were R/G-CHOP14 (56.9%) and R/G-ACVBP (43.1%). Postinduction treatments, based on interim PET results, included: standard consolidation chemotherapy (59.8%) if change in maximum standardized uptake value (ΔSUVmax) of >66% after cycle 2 and >70% after cycle 4 (PET2-/4-), intensive treatment and autologous transplantation (26.8%) if PET2+/4-, and salvage therapy (13.4%) if PET4+ (ΔSUVmax of ≤70%). Among patients with GEP data (n = 107), 38 (35.5%) were PDL1high/PDL2high. Key somatic mutations data (n = 87) included SOCS1 (70.1%), B2M (56.3%), STAT6 (49.4%), TNFAIP3 (47.1%), GNA13 (39.1%), CIITA (37.9%), CD58 (36.8%), and TP53 (29.9%). After a median follow-up of 39.5 months, 2-year progression-free survival (PFS) and overall survival (OS) rates were 86.2% and 93.2%, respectively. In a multivariate model including bulk, aaIPI, and ΔSUVmax PET2/PET4, only bulk and ΔSUVmax PET4 of ≤70% were associated with shorter PFS (hazard ratio, 4.39 [95% confidence interval (CI), 1.28-15.11] and 4.95 [95% CI, 1.71-14.3], respectively), whereas none were associated with OS. The ΔSUVmax-based interim PET4 response emerged as the strongest predictor of patient outcomes in this selected clinical trial population. This trial was registered at www.ClinicalTrials.gov as #NCT01659099.
1 个 Figure · 2 个 KM 面板
Progression-Free Survival and Overall Survival According to Interim PET2 and PET4 Response (Kaplan-Meier Analysis). (A) PFS and (B) OS according to interim PET2 and PET4 response in the PMBL set.
Figure 5. · Panel A
Panel A 是同一 Figure 5. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 5. · Panel B
Panel B 是同一 Figure 5. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。